Neurotransmitter synthesis enzymes

Neurotransmitter synthesis enzymes are a group of proteins, primarily rate-limiting hydroxylases (e.g., tyrosine hydroxylase for dopamine/norepinephrine, tryptophan hydroxylase for serotonin) and decarboxylases (e.g., aromatic L-amino acid decarboxylase), that catalyze the conversion of amino acid precursors into biogenic amine neurotransmitters like dopamine, norepinephrine, serotonin, and others in neuronal cytoplasm or vesicles.[2][4][13] These enzymes regulate neurotransmitter production through cofactor-dependent reactions involving hydroxylation, decarboxylation, and occasionally methylation, ensuring proper synaptic signaling for mood, movement, cognition, and autonomic functions.[1][2][5] Dysregulation contributes to psychiatric disorders (e.g., depression via low serotonin/dopamine synthesis) and neurodegenerative diseases (e.g., Parkinson's from reduced dopamine via tyrosine hydroxylase deficits).[3][8] Drugs target these enzymes to modulate levels: inhibitors like alpha-methyltyrosine block catecholamine synthesis for hypertension, while MAO/COMT inhibitors prevent breakdown to boost monoamines in depression.[2][3][7] Challenges include broad tissue expression causing peripheral side effects (e.g., cardiovascular risks) and incomplete selectivity, limiting direct therapeutic use beyond catabolic enzyme inhibitors.[3][9]

Other names

Monoamine synthesis enzymesBiogenic amine biosynthetic enzymesAromatic L-amino acid decarboxylase enzymes

Inhibition of synthesis enzymes (e.g., tyrosine hydroxylase blockade reduces catecholamine production); Inhibition of catabolic enzymes (e.g., MAO/COMT inhibition increases neurotransmitter levels); Vesicular transporter disruption affecting synthesis packaging